A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma

Trial Profile

A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs MK 2206 (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jan 2017 Results of futility analysis (n=43), published in the Annals of Oncology
    • 03 Jan 2017 Status changed from active, no longer recruiting to discontinued, as the trial met the futility criteria at the planned interim analysis, according to the results published in the Annals of Oncology
    • 19 Nov 2015 Planned number of patients changed from 105 to 114 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top